Long-term safety study of ORKA-001 for plaque psoriasis
Part of Skin clinical trials.
This study is a continuation for people who already took ORKA-001 for plaque psoriasis and did well. It tests whether staying on the medicine keeps helping without any new safety concerns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed the earlier ORKA-001 study without any serious side effects that forced you to stop
- You did not develop another type of psoriasis during the earlier study
- You are not pregnant or breastfeeding
- You are willing to use effective birth control if you could become pregnant or get someone pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called ORKA-002 for people with moderate-to-severe plaque psoriasis. It aims to see how well different doses work and if they are safe. You may qualify if your psoriasis covers at least 10% of your body or if it has not responded well enough to other treatments.
This trial tests a new study drug (ZP9830) to see if it is safe and works well for people with plaque psoriasis. You would receive the treatment for 8 weeks, and the study will check how your skin responds.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study tests an investigational drug called SHR-1139 for people with moderate-to-severe plaque psoriasis who have not responded well to previous biologic treatments. The goal is to see if it can reduce psoriasis symptoms safely.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.